关于聘任公司内部审计负责人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为进一步完善上海辰光医疗科技股份有限公司(以下简称"公司")治理结 构，根据《北京证券交易所股票上市规则》、《上海辰光医疗科技股份有限公司章 程》及《上海辰光医疗科技股份有限公司内部审计制度》等相关规定，公司于 2025 年 7 月 8 日召开第五届董事会第十九次会议，审议通过了《关于聘任公司 内部审计负责人的议案》，同意聘任罗妮女士为公司内部审计负责人，任职期限 自公司董事会审议通过之日起至第五届董事会任期届满之日止。 证券代码：430300 证券简称：辰光医疗 公告编号：2025-089 上海辰光医疗科技股份有限公司 截至目前，罗妮女士未直接持有公司股份，与公司董事、监事、高级管理人 员及持有公司 5%以上股份的股东、实际控制人之间不存在关联关系，未受过中 国证监会、证券交易所及其他有关部门处罚和惩戒，不存在因涉嫌犯罪被司法机 关立案侦查或涉嫌违法违规被中国证券监督管理委员会立案稽查的情形，亦不属 于失信被执行人，其任 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-055 上海辰光医疗科技股份有限公司 关于取消监事会并修订《公司章程》的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、取消监事会并修订《公司章程》的原因及依据 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章程指 引》 等规定，由董事会审计委员会行使监事会的相关职权，公司拟取消监事会， 同时废止《监事会议事规则》。 二、修订内容 | 务承担责任。 | | | --- | --- | | 第九条 本公司章程自生效之日 | 第十一条 本公司章程自生效之日 | | 起，即成为规范公司的组织与行为、公 | 起，即成为规范公司的组织与行为、公 | | 司与股东、股东与股东之间权利义务关 | 司与股东、股东与股东之间权利义务关 | | 系的，具有法律约束力的文件，对公司、 | 系的具有法律约束力的文件，对公司、 | | 股东、董事、监事、高级管理人员具有 | 股东、董事、高级管理人员具有法律约 | | 法律约束力的文件。依 ...

Core Viewpoint - The medical device industry experienced a slight decline of 0.04% as of the market close on June 11, with a net outflow of approximately 238.92 million in capital [1] Group 1: Market Performance - A total of 47 stocks in the sector increased in value, while 70 stocks saw a decline [1] - The top-performing stocks included: - Haorunbo (4.39%) - AoJing Medical (4.36%) - Sanor Bio (4.27%) - Tianzhihang-U (3.22%) - Huitai Medical (3.0%) [1][1] Group 2: Notable Declines - The stocks with the largest declines included: - Chenguang Medical (-2.8%) - Guanhao Biological (-2.72%) - Chunli Medical (-2.44%) - Kaili Medical (-2.12%) - Ruimaite (-1.76%) [1][1][1] - Notable net capital outflows were observed in: - Chenguang Medical (-25.14 million) - Guanhao Biological (-38.67 million) - Chunli Medical (-5.48 million) [1][1]

Company Overview - Chuangguang Medical's closing price on June 9 was 20.84 yuan, an increase of 4.67%, with a latest price-to-book ratio of 8.15 and a total market capitalization of 1.789 billion yuan [1] - The company specializes in the research, production, and sales of medical imaging superconducting MRI equipment and core hardware, as well as special magnets for scientific research [1] - Major products include nuclear magnetic resonance systems, superconducting magnets, RF detectors, gradient coils, RF amplifiers, and gradient amplifiers [1] - The company is recognized as a high-tech enterprise focusing on independent research and development, having received several accolades including "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" [1] Patent and Intellectual Property - As of December 31, 2024, the company holds a total of 91 valid patents, including 21 invention patents, 60 utility model patents, and 8 design patents [1] - The company has also obtained 5 software copyrights and has 30 domestic patent applications and 6 PCT patent applications under review [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 25.0744 million yuan, representing a year-on-year increase of 20.21% [1] - The net profit for the same period was -8.5827 million yuan, showing a year-on-year change of 5.22% [1] - The sales gross margin was reported at 30.84% [1] Industry Comparison - Chuangguang Medical's PE (TTM) is -29.61, while the industry average is 50.64, indicating a significant disparity [2] - The company's market capitalization stands at 1.789 billion yuan, compared to the industry median of 50.67 billion yuan [2]

Core Viewpoint - The article highlights the financial performance and market position of Chenguang Medical, emphasizing its focus on R&D in the medical imaging sector and its recent financial results [1]. Company Overview - Chenguang Medical specializes in the research, production, and sales of superconducting MRI equipment and core hardware, as well as specialized magnets for scientific research [1]. - The company has been recognized as a high-tech enterprise, receiving various accolades such as "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" in Shanghai [1]. Financial Performance - As of the first quarter of 2025, Chenguang Medical reported a revenue of 25.07 million yuan, representing a year-on-year increase of 20.21% [1]. - The net profit for the same period was -8.58 million yuan, showing a year-on-year change of 5.22% [1]. - The company's gross profit margin stood at 30.84% [1]. Market Position - Chenguang Medical's latest closing price was 20.7 yuan, with a market capitalization of 1.777 billion yuan and a price-to-book ratio of 8.10 [1]. - The company holds 91 valid patents, including 21 invention patents and 60 utility model patents, indicating a strong emphasis on innovation [1]. Industry Comparison - Chenguang Medical's price-to-earnings (P/E) ratio (TTM) is -29.41, which is significantly lower than the industry average of 50.80 [2]. - The industry median P/E ratio is 36.71, suggesting that Chenguang Medical is currently undervalued compared to its peers [2].

Group 1: Market Overview - The market has seen an increase, surpassing 4200, driven by a court ruling invalidating tariffs imposed by the US, which has boosted global risk appetite [1] - The strongest sectors today include autonomous driving and stablecoins, indicating a shift in investor focus [1] Group 2: Nuclear Fusion Research - The Southwestern Institute of Physics has achieved a new operational record for fusion devices in China, highlighting advancements in nuclear fusion research [2][1] - This development raises questions about the potential for this niche sector to gain traction and attract investment [2] Group 3: Company Involvement in Nuclear Fusion - Yongding Co., Ltd. has achieved leading performance in wire rod length and low-temperature strong magnetic field applications, with products used in superconducting induction heating and fusion magnets, maintaining close cooperation with the Southwestern Institute of Physics [6] - Chenguang Medical has ongoing technical communication with the Southwestern Institute regarding the supply of superconducting magnets, contingent on specific procurement needs [7] - Qiaoyuan Co. has established a reputation in the medical sector and maintains relationships with military research institutions, including the Southwestern Institute [8] - Lansi Heavy Industry is involved in the development of nuclear fusion-related products and has successfully applied a new type of heat exchanger in a fusion engineering project [9][10] - Guoguang Electric has received a provincial science and technology award for a project in collaboration with the Southwestern Institute focused on high-sensitivity leak detection technology for fusion components [10] - Antai Technology is at the forefront of research and manufacturing in fusion filter components, collaborating with the Southwestern Institute [11] - Hekang New Energy provides operational and maintenance services for high-voltage water-cooled variable frequency systems used by the Southwestern Institute [11] - Jingye Intelligent is exploring cooperation in remote operation and maintenance technology for fusion reactors with the Southwestern Institute [12] - Yingjie Electric serves various research institutions, including the Southwestern Institute, providing power supplies for scientific research and experimental testing [13]

Core Viewpoint - The financial performance of Chen Guang Medical has significantly declined, with a notable drop in both revenue and net profit in recent quarters, indicating challenges in the medical equipment industry and increased competition [2][4][6]. Financial Performance - In Q1 2025, Chen Guang Medical reported total revenue of 25.07 million yuan, with a net profit attributable to shareholders of -8.58 million yuan [2][8]. - The company's net profit for 2024 was -60.90 million yuan, a year-on-year decline of 416.85%, while the non-recurring net profit also saw a significant drop of 268.45% [6][8]. - The revenue for 2024 decreased by 28.16% to 119 million yuan, following an 11.08% decline in 2023 [5][6]. Business Challenges - The decline in revenue is attributed to a downturn in the domestic large medical equipment industry, particularly in the sales of MRI systems and components [4][8]. - The company faces increased operational costs, with selling expenses rising by 56.39% and R&D expenses increasing by 72.81%, leading to a spike in the expense ratio to 76.34% [8]. - Chen Guang Medical is transitioning from a parts supplier to a complete system provider, which has resulted in former clients becoming competitors, creating uncertainty in future sales [8]. Market Context - The global medical imaging market was valued at approximately 310 billion yuan in 2020, with a stable growth rate, while the Chinese market is rapidly expanding, projected to grow from 53.7 billion yuan in 2020 to 24.4 billion yuan by 2030 [11][12]. - Major international players like GE Healthcare, Philips, and Siemens dominate the MRI equipment market, holding significant market shares [11][12]. Company Background - Chen Guang Medical was founded in 2004 and specializes in the research, development, and production of MRI systems and components [4][5]. - The company went public on the Beijing Stock Exchange in December 2022, following a period of steady growth from 2019 to 2021 [5][6].

Market Overview - On May 23, the total trading volume of stocks on the Beijing Stock Exchange reached 1.269 billion shares, with a total transaction value of 27.181 billion yuan, a decrease of 10.005 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 57 stocks closed higher, accounting for 21.43% of the total, with notable gainers including Chenguang Medical, Changfu Co., and Senxuan Pharmaceutical, which rose by 14.96%, 10.12%, and 9.73% respectively [1] - Conversely, 208 stocks closed lower, with the largest declines seen in Kexin New Materials, Shengnan Technology, and Air China Ocean, which fell by 9.04%, 8.54%, and 7.89% respectively [1] Trading Activity - A total of 87 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Jinbo Biological, Changfu Co., and Wuxin Tunnel Equipment, at 813 million yuan, 597 million yuan, and 517 million yuan respectively [1] - In terms of trading activity, 48 stocks had a turnover rate exceeding 10%, with 8 stocks exceeding 20%. Additionally, 94 stocks had turnover rates between 5% and 10%, while 122 stocks had turnover rates between 1% and 5% [1] - The stocks with the highest turnover rates included Ningxin New Materials, Chenguang Medical, and Changfu Co., with turnover rates of 33.42%, 32.11%, and 31.21% respectively [1] Stock Performance - The closing prices and performance of notable stocks included: - Jinbo Biological: Closing price of 497.70 yuan, up 0.85%, turnover rate of 3.54%, transaction value of 812.56 million yuan [1] - Changfu Co.: Closing price of 45.90 yuan, up 10.12%, turnover rate of 31.21%, transaction value of 597.47 million yuan [1] - Wuxin Tunnel Equipment: Closing price of 41.27 yuan, down 7.28%, turnover rate of 14.02%, transaction value of 516.61 million yuan [1] - Chenguang Medical: Closing price of 21.90 yuan, up 14.96%, turnover rate of 32.11%, transaction value of 473.16 million yuan [1] - Air China Ocean: Closing price of 10.04 yuan, down 7.89%, turnover rate of 15.90%, transaction value of 473.14 million yuan [1]

Group 1 - The controllable nuclear fusion sector in A-shares experienced a significant surge, with the sector index rising over 4% and 30 stocks within the sector increasing in value [1][2] - Notable performers included Xue Ren Co., Ltd. (002639) and Rongfa Nuclear Power (002366), both hitting the daily limit up, while Chen Guang Medical (430300) saw an increase of over 26% [1][2] - The controllable nuclear fusion index reached 1476.66, reflecting a rise of 3.71% [2] Group 2 - The U.S. nuclear energy sector saw a collective surge in stock prices, which positively influenced Asian nuclear power stocks, leading to gains in the Hong Kong market [3][4] - The China General Nuclear Power Index (887716.WI) rose by 3.6%, while the Nuclear Power Index (884046.WI) increased by 2.32% [3][4] Group 3 - Recent developments in the nuclear energy sector indicate a critical phase in the construction of nuclear fusion experimental reactors, with significant progress expected [5] - The BEST reactor project has officially commenced assembly, aiming for completion by 2027, while the CRAFT reactor is projected to be completed by the end of 2025 [5] - The market anticipates a rapid development in the controllable nuclear fusion industry, with increased project tenders and commercialization efforts expected in 2025 [5]

Core Viewpoint - The A-share market for controllable nuclear fusion has experienced a significant surge, with multiple stocks reaching their daily limit up, driven by positive market sentiment and favorable policy developments [1][2][8]. Group 1: Market Performance - The A-share controllable nuclear fusion sector saw explosive growth on May 23, with stocks like Hahwa Huasheng and Chenguang Medical hitting the daily limit up, while others like Xue Ren Co. and Rongfa Nuclear Power also showed substantial gains [1][2]. - In the Hong Kong stock market, nuclear power and energy sectors also strengthened, with China General Nuclear Power Mining rising over 7%, influenced by movements in the US nuclear energy sector [3]. Group 2: Policy and Technological Developments - The global energy demand is rising, and traditional fossil fuel supplies are becoming scarce, leading to a shift towards clean energy, with nuclear energy being a key focus for many countries [4]. - The Chinese government is actively promoting the nuclear energy industry, with the establishment of a Nuclear Power Engineering Quota Expert Committee to oversee technical reviews [5]. - Significant technological advancements have been made, such as the completion of the world's largest superconducting magnet system for the International Thermonuclear Experimental Reactor (ITER), marking a crucial step towards controllable nuclear fusion [5]. Group 3: Industry Outlook - The nuclear energy sector is expected to grow significantly, with projections indicating that global nuclear power capacity could exceed 1.1 billion kilowatts by 2050, highlighting the potential for development in this area [6]. - Analysts are optimistic about the future of the nuclear fusion industry, with expectations that recent advancements in research and development will accelerate the commercialization process [7]. - The competitive landscape is intensifying, particularly between the US and China, as nuclear fusion emerges as a critical area for technological competition, similar to artificial intelligence [7].